	US 12,144,819 B2
	Pharmaceutical composition and use
Jeffrey Missling, Eden Prairie, MN (US)
Assigned to SPINETHERA, Plymouth, MN (US)
Filed by SpineThera, Plymouth, MN (US)
Filed on Jun. 15, 2021, as Appl. No. 17/348,471.
Application 17/348,471 is a continuation of application No. 16/437,201, filed on Jun. 11, 2019, granted, now 11,058,692.
Application 16/437,201 is a continuation of application No. 15/421,003, filed on Jan. 31, 2017, granted, now 10,350,222.
Application 15/421,003 is a continuation of application No. 14/561,797, filed on Dec. 5, 2014, granted, now 9,572,771.
Application 14/561,797 is a continuation of application No. 13/752,931, filed on Jan. 29, 2013, granted, now 8,927,529.
Claims priority of provisional application 61/592,438, filed on Jan. 30, 2012.
Prior Publication US 2021/0379083 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/50 (2006.01); A61K 47/10 (2017.01); A61K 47/34 (2017.01)

CPC A61K 31/573 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 9/146 (2013.01); A61K 9/16 (2013.01); A61K 9/1647 (2013.01); A61K 9/5031 (2013.01); A61K 47/10 (2013.01); A61K 47/34 (2013.01); A61K 9/0051 (2013.01)]

16 Claims

1. A kit comprising:

(a) a first container comprising microparticles comprising an active pharmaceutical ingredient agent and at least one polymer, wherein the microparticles have a d₉₀of less than about 7 μm wherein at least one polymer comprises a block copolymer comprising a polyethylene glycol (PEG) block, and the active pharmaceutical ingredient agent is present in a weight of up to about 40% the weight of the total polymer; and

(b) a second container comprising a carrier vehicle.